case_images: PMC6884546_01
case_images: PMC6884546_02
case_images: MRI of the brain and spine with and without contrast at diagnosis. a, b T1-weighted axial images show enhancement of the bilateral fifth cranial nerves after the administration of gadolinium contrast. c, d There is enhancement of the bilateral seventh-eighth cranial nerve complexes. e Sagittal T1-weighted post-contrast spine images demonstrate patchy circumferential enhancement along the thoracic and lumbar spinal cord (arrow heads) and enhancement of the cauda equina nerve roots (arrows), related to leptomeningeal carcinomatosis.
case_images: 41523_2019_139_Fig1_HTML.jpg
case_images: PMC6884546_02_41523_2019_139_Fig1_HTML.jpg
case_images: Fig1
case_images: PMC6884546_03
case_images: MRI brain and spine, 12 months following treatment with olaparib. a, b Axial T1-weighted post-contrast images show resolved enhancement of the fifth cranial nerves (a, arrowhead) and seventh-eighth cranial nerves complexes (b, arrows). Linear enhancement adjacent to the right seventh-eighth cranial nerve complex was consistent with a vascular loop. c Sagittal T1-weight MRI of the spine, post contrast, shows minimal enhancement anterior to the thoracic spinal cord (arrowhead) and subtle enhancement within the cauda equina nerve roots (arrow).
case_images: 41523_2019_139_Fig2_HTML.jpg
case_images: PMC6884546_03_41523_2019_139_Fig2_HTML.jpg
case_images: Fig2
case_images: One year from LC diagnosis and initiation of olaparib, brain MRI showed complete resolution of previous cranial nerve enhancement (Fig. 2a, b). Spinal MRI at that time showed resolution of circumferential thoracic and lumbar spine enhancement, with only vague enhancement and no thickening of the cauda equina nerve roots (Fig. 2c).